[go: up one dir, main page]

DE60019741D1 - Nanopartikelzusammensetzungen enthaltend eplerenon - Google Patents

Nanopartikelzusammensetzungen enthaltend eplerenon

Info

Publication number
DE60019741D1
DE60019741D1 DE60019741T DE60019741T DE60019741D1 DE 60019741 D1 DE60019741 D1 DE 60019741D1 DE 60019741 T DE60019741 T DE 60019741T DE 60019741 T DE60019741 T DE 60019741T DE 60019741 D1 DE60019741 D1 DE 60019741D1
Authority
DE
Germany
Prior art keywords
compositions containing
nanoparticle compositions
containing eplerenone
eplerenone
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60019741T
Other languages
English (en)
Other versions
DE60019741T2 (de
Inventor
S Thosar
D Gokhale
S Tolbert
Subhash Desai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of DE60019741D1 publication Critical patent/DE60019741D1/de
Application granted granted Critical
Publication of DE60019741T2 publication Critical patent/DE60019741T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60019741T 1999-12-08 2000-12-04 Nanopartikelzusammensetzungen enthaltend eplerenon Expired - Fee Related DE60019741T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16965899P 1999-12-08 1999-12-08
US169658P 1999-12-08
US20898100P 2000-06-02 2000-06-02
US208981P 2000-06-02
PCT/US2000/030179 WO2001041770A2 (en) 1999-12-08 2000-12-04 Nanoparticulate eplerenone compositions

Publications (2)

Publication Number Publication Date
DE60019741D1 true DE60019741D1 (de) 2005-06-02
DE60019741T2 DE60019741T2 (de) 2006-03-02

Family

ID=26865266

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019741T Expired - Fee Related DE60019741T2 (de) 1999-12-08 2000-12-04 Nanopartikelzusammensetzungen enthaltend eplerenon

Country Status (13)

Country Link
US (2) US20020006919A1 (de)
EP (1) EP1175220B1 (de)
AR (1) AR026745A1 (de)
AT (1) ATE293977T1 (de)
AU (1) AU1756201A (de)
CO (1) CO5251419A1 (de)
DE (1) DE60019741T2 (de)
DK (1) DK1175220T3 (de)
ES (1) ES2240209T3 (de)
HK (1) HK1039897A1 (de)
PE (1) PE20010910A1 (de)
PT (1) PT1175220E (de)
WO (1) WO2001041770A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SI1353696T1 (sl) 2001-01-26 2007-04-30 Schering Corp Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003030872A2 (en) * 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions having a combination of particles for immediate release and for controlled release
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) * 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
DE10164510A1 (de) 2001-12-20 2003-07-10 Schering Ag Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes
US7008979B2 (en) 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
JP2006508189A (ja) 2002-11-06 2006-03-09 シェーリング　コーポレイション 自己免疫障害の処置のためのコレステロール吸収インヒビター
US8003690B2 (en) * 2002-12-13 2011-08-23 Jagotec Ag Topical nanoparticulate spironolactone formulation
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7208486B2 (en) * 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE406364T1 (de) 2003-03-07 2008-09-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
WO2007059422A2 (en) * 2005-11-10 2007-05-24 Wyeth Pharmaceutical formulations containing 5-cyclopropyl-2(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl) amino]-n-methyl-1-benzofuran-3-carboxamide and method of making same
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2008011051A1 (en) * 2006-07-17 2008-01-24 Liquidia Technologies, Inc. Nanoparticle fabrication methods, systems, and materials
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
WO2008027571A2 (en) * 2006-08-30 2008-03-06 Liquidia Technologies, Inc. Nanoparticles having functional additives for self and directed assembly and methods of fabricating same
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2008074098A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
WO2009010837A2 (en) * 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
US9082409B2 (en) * 2008-08-28 2015-07-14 Avaya Inc. Binary-caching for XML documents with embedded executable code
EP2201977A1 (de) * 2008-12-23 2010-06-30 Siegfried Generics International AG Dosiervorrichtung zur Erzeugung eines Gasstromes mit einem in diesem fein verteilten Wirkstoff
US20110268775A1 (en) * 2009-01-06 2011-11-03 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
WO2013095311A1 (en) 2011-11-25 2013-06-27 Mahmut Bilgic Inhalation device
CN103263398B (zh) * 2013-06-06 2014-05-14 山东罗欣药业股份有限公司 一种头孢地尼组合物胶囊及其制备方法
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
CN109925293B (zh) * 2019-03-15 2022-02-01 南京卡文迪许生物工程技术有限公司 依普利酮口服固体制剂及其制备方法
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)

Also Published As

Publication number Publication date
WO2001041770A2 (en) 2001-06-14
DK1175220T3 (da) 2005-08-29
EP1175220B1 (de) 2005-04-27
PE20010910A1 (es) 2001-09-10
US20030212053A1 (en) 2003-11-13
AR026745A1 (es) 2003-02-26
US20020006919A1 (en) 2002-01-17
WO2001041770A3 (en) 2001-11-22
HK1039897A1 (zh) 2002-05-17
PT1175220E (pt) 2005-07-29
CO5251419A1 (es) 2003-02-28
ATE293977T1 (de) 2005-05-15
EP1175220A2 (de) 2002-01-30
ES2240209T3 (es) 2005-10-16
AU1756201A (en) 2001-06-18
DE60019741T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
DE60019741D1 (de) Nanopartikelzusammensetzungen enthaltend eplerenon
ATE285222T1 (de) Antiperspirant-zusammensetzungen
ITMI991754A0 (it) Composizioni cosmetiche
PT1242087E (pt) Composicoes farmaceuticas
IS6120A (is) Lyfjablanda
NO20012782L (no) Mikroniserte eplerenon sammensetninger
DE69900634D1 (de) Shampoozusammensetzungen
EA199900373A3 (ru) Фармацевтические композиции
HUP0202275A3 (en) Mousse-forming shampoo compositions
ATE258418T1 (de) Shampoozusammensetzungen
DE60007731D1 (de) Schweisshemmende zusammensetzungen
AR028087A1 (es) Composiciones cosmeticas
DE60025624D1 (de) Farbstabile polyarylat enthaltende zusammensetzungen
DE69925167D1 (de) Hochwitterungsbeständige pulverlackzusammensetzung
FI990089L (fi) Maalikoostumukset
DE69943245D1 (de) Gaserzeugende zusammensetzung
PT1239832E (pt) Composicoes farmaceuticas
AR027959A1 (es) Composiciones cosmeticas
DE60000022D1 (de) Verbesserte teilchenförmige Zusammensetzungen
DE60011924D1 (de) Ciclesonidhaltige wässrige arzneizusammensetzungen
DE60008839D1 (de) Duftstoff-Zusammensetzung
ATE297187T1 (de) Resorcinenthaltende zusammensetzung
AR027981A1 (es) Composiciones cosmeticas
ID27329A (id) Komposisi penghambat
IS2200B (is) Lyfjasamsetningar

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee